L'IMPIEGO DEL MEDROSSI-PROGESTERONE ACETATO AD ALTI DOSAGGI NELLA TERAPIE PALLIATIVA DEL CARCINOMA MAMMARIO IN FASE AVANZATA. ESPERIENZA CLINICA SU 44 CASI

Translated title of the contribution: The use of medroxyprogesterone acetate in high doses in palliative treatment of advanced mammary carcinoma (clinical experience with 44 cases)

D. Amadori, A. Ravaiolli, F. Barbanit

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

MAP was used in high doses (1 g/die up to a total dose of 45 - 50 g) in 44 cases of advanced mammary carcinoma (IIIrd and IVth stage of the T.N.M. classification), evaluated according to the criteria proposed by CBCG. The excellent tolerance to the drug, even at such high doses, is stressed. Therapeutic responses were best in cases of metastasis in the soft and bony tissues and in cases of pulmonary metastasis. It is pointed out that the effectiveness of the treatment is particularly evident in patients in whom the free interval has exceeded two years and in patients in the menopause for more than five years. In the light of results obtained, the possibility of introducing the drug into the therapeutic strategy of this condition is discussed.

Original languageItalian
Pages (from-to)3967-3980
Number of pages14
JournalMinerva Medica
Volume68
Issue number59
Publication statusPublished - 1977

Fingerprint

Medroxyprogesterone Acetate
Palliative Care
Breast Neoplasms
Drug Tolerance
Neoplasm Metastasis
Neoplasm Staging
Menopause
Lung
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

L'IMPIEGO DEL MEDROSSI-PROGESTERONE ACETATO AD ALTI DOSAGGI NELLA TERAPIE PALLIATIVA DEL CARCINOMA MAMMARIO IN FASE AVANZATA. ESPERIENZA CLINICA SU 44 CASI. / Amadori, D.; Ravaiolli, A.; Barbanit, F.

In: Minerva Medica, Vol. 68, No. 59, 1977, p. 3967-3980.

Research output: Contribution to journalArticle

@article{b99f8483e2be4e2fad36ccff6573b14e,
title = "L'IMPIEGO DEL MEDROSSI-PROGESTERONE ACETATO AD ALTI DOSAGGI NELLA TERAPIE PALLIATIVA DEL CARCINOMA MAMMARIO IN FASE AVANZATA. ESPERIENZA CLINICA SU 44 CASI",
abstract = "MAP was used in high doses (1 g/die up to a total dose of 45 - 50 g) in 44 cases of advanced mammary carcinoma (IIIrd and IVth stage of the T.N.M. classification), evaluated according to the criteria proposed by CBCG. The excellent tolerance to the drug, even at such high doses, is stressed. Therapeutic responses were best in cases of metastasis in the soft and bony tissues and in cases of pulmonary metastasis. It is pointed out that the effectiveness of the treatment is particularly evident in patients in whom the free interval has exceeded two years and in patients in the menopause for more than five years. In the light of results obtained, the possibility of introducing the drug into the therapeutic strategy of this condition is discussed.",
author = "D. Amadori and A. Ravaiolli and F. Barbanit",
year = "1977",
language = "Italian",
volume = "68",
pages = "3967--3980",
journal = "Minerva Medicolegale e Archivio di Antropologia Criminale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "59",

}

TY - JOUR

T1 - L'IMPIEGO DEL MEDROSSI-PROGESTERONE ACETATO AD ALTI DOSAGGI NELLA TERAPIE PALLIATIVA DEL CARCINOMA MAMMARIO IN FASE AVANZATA. ESPERIENZA CLINICA SU 44 CASI

AU - Amadori, D.

AU - Ravaiolli, A.

AU - Barbanit, F.

PY - 1977

Y1 - 1977

N2 - MAP was used in high doses (1 g/die up to a total dose of 45 - 50 g) in 44 cases of advanced mammary carcinoma (IIIrd and IVth stage of the T.N.M. classification), evaluated according to the criteria proposed by CBCG. The excellent tolerance to the drug, even at such high doses, is stressed. Therapeutic responses were best in cases of metastasis in the soft and bony tissues and in cases of pulmonary metastasis. It is pointed out that the effectiveness of the treatment is particularly evident in patients in whom the free interval has exceeded two years and in patients in the menopause for more than five years. In the light of results obtained, the possibility of introducing the drug into the therapeutic strategy of this condition is discussed.

AB - MAP was used in high doses (1 g/die up to a total dose of 45 - 50 g) in 44 cases of advanced mammary carcinoma (IIIrd and IVth stage of the T.N.M. classification), evaluated according to the criteria proposed by CBCG. The excellent tolerance to the drug, even at such high doses, is stressed. Therapeutic responses were best in cases of metastasis in the soft and bony tissues and in cases of pulmonary metastasis. It is pointed out that the effectiveness of the treatment is particularly evident in patients in whom the free interval has exceeded two years and in patients in the menopause for more than five years. In the light of results obtained, the possibility of introducing the drug into the therapeutic strategy of this condition is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0017732777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017732777&partnerID=8YFLogxK

M3 - Articolo

C2 - 74811

AN - SCOPUS:0017732777

VL - 68

SP - 3967

EP - 3980

JO - Minerva Medicolegale e Archivio di Antropologia Criminale

JF - Minerva Medicolegale e Archivio di Antropologia Criminale

SN - 0026-4806

IS - 59

ER -